Search / Trial NCT00000491

Aspirin-Myocardial Infarction Study (AMIS)

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Oct 27, 1999

Trial Information

Current as of November 14, 2024

Completed

Keywords

ClinConnect Summary

BACKGROUND:

It had been postulated that thrombosis plays a major role in the late stages of coronary artery occlusion. Platelet aggregation is a large component in the formation of arterial thrombi. Theoretically, an agent which prevents the aggregation of platelets would be of value in people with coronary artery disease. Aspirin, in small doses, inhibits platelet aggregation for prolonged periods of time, and therefore might be expected to prevent or retard the occlusion of coronary arteries. This would be reflected in a decrease in the incidence of myocardial infarction and a decrease i...

Gender

ALL

Eligibility criteria

  • Men and women, ages 30 to 69. Had a documented myocardial infarction.

Trial Officials

Allan Barker

Salt Lake Clinic Research Foundation

David Berkson

Unity Health Toronto

William Berstein

Icahn School of Medicine at Mount Sinai

Nemat Borhani

University of California, Davis

Elmer Cooper

Santa Rosa Medical Center

Leonard Dreifus

Lankenau Hospital

Noble Fowler

University of Cincinnati

Phillip Frost

USPHS Hospital

Mario Garcia-Palmieri

University of Puerto Rico Medical Science Campus

Hugh Gilmore

University of Miami

Sidney Goldstein

Henry Ford Hospital

Olga Haring

Northwestern University

J. Hoover

University of Washington

Richard Hutchinson

University of Mississippi Medical Center

William Krol

University of Maryland at Baltimore

Peter Kuo

Rutgers Medical School

Charles, Laubach

Institute for Medical Education and Research

Bernard Lewis

Palo Alto Medical Research Foundation

Jessie Marmorston

University of Southern California

J. McNamara

Pacific Health Research Institute

Dayton Miller

U.S. Centers for Disease Control and Prevention

Thaddeus Prout

Greater Baltimore Medical Center

David Richardson

Virginia Commonwealth University

Jorge Rios

George Washington University

Paul Samuel

Long Island Jewish-Hillside Medical Center

Stephen Scheidt

Weill Medical College of Cornell University

Robert Schlant

Emory University

Henry Schoch

University of Michigan

James Schoenberger

Rush University Medical Center

Marvin Segal

MOUNT SINAI HOSPITAL

Pantel Vokonas

Boston Health and Hospitals Department

C. Williams

Ogden Research Foundation

Gary Wilner

NorthShore University HealthSystem

About National Heart, Lung, And Blood Institute (Nhlbi)

The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials